Home > Licensing Opportunities
Pharmaceutical licensing opportunities from Asia Pacific | Oncology | formulation of paclitaxel that permits higher dosing - on market (Korea), phase II (USA)
dual mode of action cytotoxic with expected improvements in anti-tumour activity & selectivity, lower toxicity and no cross-resistance vs. competing products - early preclinical
therapeutic vaccine for cancer that stimulates strong Th1 and Th2 responses; potent in vivo tumour suppression in bladder/colon cancer models - early preclinical | | Diabetes | PPAR pan-agonist for type 2 diabetes - phase II | | Antimicrobials | antimicrobial peptide that destroys bacterial cell membranes; for topical indications - preclinical | | Wound Care | polypeptide for ulcers and wound healing with an angiogenic mode of action - preclinical | | Vaccines | adjuvant that stimulates strong Th1 and Th2 responses - early preclinical
double-attenuated influenza vaccine that can be delivered via nasal spray; based on a high-growth phenotype, the vaccine provides early protection - early preclinical | | CNS | novel compounds (melatonergic agonists, NMDA antagonists, neuroprotective heterodimers) for neurodegenerative, psychiatric and sleep-related disorders - research / early preclinical | Ophthalmology
(China only) |  |
All of the above opportunities are either patented or have international/PCT patent filings. |
+852 6200 8250
